RTN4 Protein (Nogo)

📖 Wiki Page

protein996 wordssynced 2026-04-02

RTN4 Protein (Reticulon-4 / Nogo)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">RTN4 Protein (Nogo)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>RTN4</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>RTN4 (Nogo)</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=RTN4" target="_blank">Search UniProt</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">11 edges</a></td>
</tr>
</table>

Overview

...

RTN4 Protein (Reticulon-4 / Nogo)

Overview

Reticulon-4 (RTN4), commonly known as Nogo, is the most studied member of the reticulon protein family and a potent inhibitor of axonal regeneration in the central nervous system.[@bhatt2006][@schwab2010] Encoded by the [RTN4](/genes/rtn4) gene, Nogo exists in three major isoforms (Nogo-A, Nogo-B, Nogo-C) with distinct tissue distribution and functional profiles.[@bhatt2006] Nogo-A signals through the Nogo receptor complex (NgR1/LINGO-1/p75NTR or TROY) to activate RhoA-ROCK signaling, inducing growth cone collapse and blocking axonal sprouting.[@schwab2010] Beyond its canonical role in CNS injury, accumulating evidence implicates Nogo-A signaling in [Alzheimer's Disease](/diseases/alzheimers-disease), [multiple sclerosis](/diseases/multiple-sclerosis), and age-related synaptic decline.[@park2006][@he2004]

Structure

RTN4 produces three principal isoforms through alternative promoter usage and splicing:

Nogo-A (~200 kDa): The largest isoform, predominantly expressed in oligodendrocytes and some [neurons](/entities/neurons). Contains two inhibitory domains — the Nogo-66 loop (66 amino acid extracellular segment between two transmembrane domains) that binds NgR1, and the Nogo-A-specific amino-terminal domain (amino-Nogo/NiG) that signals through sphingosine-1-phosphate receptor 2 (S1PR2).[@bhatt2006][@schwab2010]
Nogo-B (~55 kDa): Widely expressed across vascular endothelium, smooth muscle, and immune cells. Lacks the amino-Nogo domain but retains the Nogo-66 region. Functions primarily in vascular remodeling through the Nogo-B receptor (NgBR/NUS1).[@bhatt2006]
Nogo-C (~25 kDa): Expressed in skeletal muscle and some neuronal populations. Contains only the reticulon homology domain (RHD) and Nogo-66. Its neurological function remains less characterized.[@bhatt2006]

All isoforms share the C-terminal RHD, which contains two hydrophobic hairpin domains that anchor the protein in the endoplasmic reticulum membrane and shape ER tubular morphology.[@bhatt2006]

Normal Function

Axon Growth Inhibition

Nogo-A is a major myelin-associated inhibitor that restricts axonal plasticity in the adult CNS.[@schwab2010] Through the Nogo-66 domain binding to the NgR1/LINGO-1/p75NTR receptor complex, Nogo-A activates the small GTPase RhoA and its downstream effector ROCK (Rho-associated kinase), leading to growth cone collapse, neurite retraction, and inhibition of axonal sprouting.[@schwab2010] This signaling pathway serves to stabilize neural circuitry in the mature brain, preventing inappropriate axonal reorganization.

Myelin Stability

In [oligodendrocytes](/cell-types/oligodendrocytes), Nogo-A localizes to the innermost myelin wraps (adaxonal membrane) where it contributes to myelin sheath structural integrity and periodicity.[@bhatt2006] Loss of Nogo-A leads to subtle myelin abnormalities in mouse models, suggesting it plays a maintenance role in the oligodendrocyte-axon unit.

ER Morphology and Calcium Signaling

Through its RHD, RTN4 shapes ER tubular networks and influences ER-mitochondrial contact sites, which are critical for calcium signaling and lipid transfer.[@bhatt2006] This housekeeping function is shared across all reticulon family members and is relevant to the ER stress component of neurodegenerative disease.

Role in Neurodegeneration

Alzheimer's Disease

Nogo-A expression is elevated in hippocampal neurons of AD patients, and its receptor NgR1 colocalizes with [amyloid plaques](/mechanisms/amyloid-cascade).[@park2006][@he2004] Several mechanistic connections have been identified:

Amyloid-beta interaction: NgR1 directly binds Aβ oligomers and fibrils, and Nogo-A/NgR1 signaling may mediate part of Aβ-induced synaptic toxicity by activating RhoA-ROCK-dependent dendritic spine retraction.[@park2006]
[APP](/entities/app-protein) processing: Nogo-A interacts with the [beta-secretase](/entities/bace1) [BACE1](/proteins/bace1-protein), and overexpression of RTN family members (including RTN3) modulates amyloidogenic APP cleavage.[@he2004]
Synaptic plasticity restriction: Age-related increases in Nogo-A signaling contribute to reduced synaptic plasticity and impaired [long-term potentiation](/mechanisms/long-term-potentiation) in aged [hippocampus](/brain-regions/hippocampus). Genetic deletion of NgR1 in aged mice restores youthful levels of ocular dominance plasticity.[@mcgee2005]

Spinal Cord Injury

Nogo-A is the primary barrier to functional axonal regeneration after spinal cord injury (SCI). Anti-Nogo-A antibodies (e.g., the humanized antibody ATI355/NG-101) promote axonal sprouting, formation of detour circuits, and functional recovery in rodent and primate SCI models.[@schwab2010][@kucher2018] Phase I clinical trials of intrathecal anti-Nogo-A antibodies in acute SCI patients have demonstrated safety and are progressing to efficacy testing.[@kucher2018]

Multiple Sclerosis

In [MS](/diseases/multiple-sclerosis), Nogo-A may limit remyelination by inhibiting oligodendrocyte precursor cell process extension needed for remyelination of denuded axons.[@karnezis2004] Anti-Nogo-A approaches are being explored as adjuncts to promote remyelination alongside immunomodulatory therapies.

Stroke Recovery

Post-stroke, Nogo-A restricts compensatory axonal sprouting from the intact hemisphere that could restore function. Anti-Nogo-A antibody treatment in rodent stroke models enhances corticospinal tract plasticity and improves skilled forelimb recovery.[@schwab2010]

Therapeutic Targeting

Anti-Nogo-A antibodies: ATI355/NG-101 (Novartis) and ozanezumab have been tested in SCI and ALS clinical trials respectively. Ozanezumab did not meet primary endpoints in ALS (Phase II), but anti-Nogo strategies continue in SCI.[@kucher2018]
NgR decoy receptors: Soluble NgR1-Fc fusion proteins that sequester Nogo-66 and other myelin inhibitors (MAG, OMgp) promote axonal regeneration in preclinical models.[@schwab2010]
ROCK inhibitors: Downstream targeting of RhoA-ROCK signaling (e.g., fasudil) bypasses the receptor level and blocks growth cone collapse regardless of the upstream inhibitor. Fasudil has been tested in stroke recovery trials.[@schwab2010]
Nogo-A in AD: Blocking NgR1 signaling to restore synaptic plasticity represents a mechanistically distinct therapeutic approach for cognitive decline, orthogonal to amyloid- or [tau](/proteins/tau)-targeting strategies.[@park2006][@mcgee2005]

External Links

[UniProt: RTN4 (Q9NQC3)](https://www.uniprot.org/uniprot/Q9NQC3)
[NCBI Gene: RTN4](https://www.ncbi.nlm.nih.gov/gene/57142)
[GeneCards: RTN4](https://www.genecards.org/cgi-bin/carddisp.pl?gene=RTN4)

References

[Bhatt DH, Otto SJ, Bhatt JM, Reticulon family members shape the endoplasmic reticulum and influence cell function (2006)](https://pubmed.ncbi.nlm.nih.gov/17403775/)

[Schwab ME, Functions of Nogo proteins and their receptors in the nervous system (2010)](https://pubmed.ncbi.nlm.nih.gov/20401166/)

[Park JH, Gimbel DA, GrandPre T, et al, Alzheimer disease amyloid-beta binds Nogo receptor and inhibits neurite outgrowth (2006)](https://pubmed.ncbi.nlm.nih.gov/17049636/)

[He W, Lu Y, Bhahani I, et al, Reticulon family members modulate BACE1 activity and amyloid-beta peptide generation (2004)](https://pubmed.ncbi.nlm.nih.gov/15282611/)

[McGee AW, Yang Y, Fischer QS, et al, Experience-driven plasticity of visual cortex limited by myelin and Nogo receptor (2005)](https://pubmed.ncbi.nlm.nih.gov/16207848/)

[Kucher K, Johns D, Maier D, et al, First-in-man intrathecal application of neurite growth-promoting anti-Nogo-A antibodies in acute spinal cord injury (2018)](https://pubmed.ncbi.nlm.nih.gov/30239613/)

[Karnezis T, Bhatt LK, et al, The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination (2004)](https://pubmed.ncbi.nlm.nih.gov/15024121/)

📖 View canonical wiki page →

RTN4 Protein (Nogo)

RTN4 Protein (Reticulon-4 / Nogo)

Overview

RTN4 Protein (Reticulon-4 / Nogo)

Overview

Structure

Normal Function

Axon Growth Inhibition

Myelin Stability

ER Morphology and Calcium Signaling

Role in Neurodegeneration

Alzheimer's Disease

Spinal Cord Injury

Multiple Sclerosis

Stroke Recovery

Therapeutic Targeting

See Also

External Links

References